Modafinil to Improve Fatiguability

Fatigue Clinical Trial

— MODIFY  

Official title:

Modafinil to Improve Fatiguability (MODIFY): Modafinil vs. Placebo Vanguard RCT

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05333250
• Other study ID #: 663439
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: April 2024
• Est. completion date: March 2026

Study information

• Verified date: November 2023
• Source: Ottawa Hospital Research Institute
• Contact: Shainuka Kannathas, HBSc
• Phone: (613) 562-6262
• Email: skannathas[@]bruyere.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the most commonly reported disabling symptoms experienced by patients with advanced cancer. However, there are currently limited evidence-based pharmacologic interventions available. The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the effect of modafinil in managing CRF and CRCI, and to test the feasibility of carrying out the study.

Description:

Background: Patients with advanced cancer often experience various disabling symptoms. Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the most common reported symptoms, yet the availability of evidence-based pharmacologic interventions is limited. CRF can be defined as a "distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning." CRF is experienced by over 75% of patients with advanced cancer. CRCI is defined as a decline in one or more areas of cognitive function, including attention and concentration, executive functioning, information processing speed, language, visuospatial skill, psychomotor ability, and memory. It is estimated that up to 40% of patients experience CRCI prior to any treatment; up to 75% during their treatment; and up to 60% upon completion of therapies. Modafinil is a psychostimulant that has been studied in the context of CRF and daytime sleepiness. Its mechanism of action is not clear, but it is thought to promote wakefulness through dopaminergic neurotransmission which has been hypothesized to play a role in CRF. Study Hypothesis: Modafinil will improve CRF and CRCI Study Objectives: 1. To estimate the effect size of modafinil in managing CRF and CRCI 2. To test the feasibility of carrying out the study (recruitment, etc.) Study Design: Randomized, placebo-controlled, double-blind, single-centre vanguard trial Sample Size & Study Population: Approximately 40 outpatients presenting ≥4/10 on the fatigue score of their screening questionnaire will be recruited. Eligible patients must be 18-75 years old with advanced cancer who have not received cytotoxic chemotherapy for at least one month. Intervention: Subjects will be randomized to receive 200 mg of modafinil or placebo once daily for one week. Study Outcome Measures: Using validated questionnaires and a digital tool, the investigators will assess the patient's fatigue (CRF), cognition (CRCI), and quality of life before and after the intervention. In addition, patients will report their global impression of change. Finally, if patients experience any adverse events (headache, nausea, vomiting, anxiety, etc.), they will report them using a standard questionnaire. Adverse events (AEs) and Serious Adverse Events (SAEs) will be documented. Expected Outcomes: Positive results should provide justification to prolong the study to complete a phase III trial. This study is important because fatigue remains a cause of suffering amongst palliative patients with cancer. Modafinil has the potential to improve patients' fatigue, cognition, and quality of life.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: March 2026
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Stage III or IV cancer diagnosis;
• Has been off cytotoxic chemotherapy for at least 6 weeks;
• Eastern Cooperative Oncology Group (ECOG) score of 0-2;
• Experiencing CRF, defined as score of 4 or greater on the Fatigue item of the Edmonton Symptom Assessment System-revised (ESAS-r);
• Prognosis of at least 3 months;
• Able to understand and communicate in English and/or French;
• Able to give first-person informed consent.

Exclusion Criteria:

• Allergy to modafinil;
• Dose change of prednisone or dexamethasone in the past 7 days or planned dose change during study period;
• Received blood transfusion in the past 2 weeks;
• Hemoglobin lower than 80 g/L measured within 2 weeks of enrolment;
• Thyroid Stimulating Hormone (TSH) above normal range (measured within 2 weeks or start date);
• Patients with known brain metastasis or primary brain tumors;
• Documented dementia diagnosis;
• Documented major psychiatric illness including major depressive episode, bipolar disorder, or schizophrenia;
• Uncontrolled hypertension, defined as blood pressure higher than 140/80;
• Inability to ingest oral capsule;
• Pregnant or lactating;
• Severe liver dysfunction, defined as newly developed liver enzyme elevation total bilirubin >3 upper limits of normal, aspartate aminotransferase or alanine aminotransferase >5 upper limits of normal.

Related Conditions & MeSH terms

• Cancer-related Cognitive Difficulties
• Cancer-related Problem/Condition
• Fatigue

Intervention

Drug:
• Modafinil
Modafinil

Other:
• Placebo
Placebo

Locations

Country	Name	City	State
Canada	The Ottawa Hospital	Ottawa	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute	Bruyere Research Institute, The Ottawa Hospital

Country where clinical trial is conducted

Canada, 

References & Publications (5)

Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C; National comprehensive cancer network. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39. doi: 10.6004/jnccn.2015.0122. — View Citation

Hovey E, de Souza P, Marx G, Parente P, Rapke T, Hill A, Bonaventura A, Michele A, Craft P, Abdi E, Lloyd A; MOTIF investigators. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer. 2014 May;22(5):1233-42. doi: 10.1007/s00520-013-2076-0. Epub 2013 Dec 17. — View Citation

Jansen CE, Cancer Basics J, Eggert I (eds) (2010) Pittsburgh, PA:oncology nursing. Society

Murillo-Rodriguez E, Barciela Veras A, Barbosa Rocha N, Budde H, Machado S. An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil. ACS Chem Neurosci. 2018 Feb 21;9(2):151-158. doi: 10.1021/acschemneuro.7b00374. Epub 2017 Dec 4. — View Citation

Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015 Mar;65(2):123-38. doi: 10.3322/caac.21258. Epub 2014 Dec 5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fatigue	Change in fatigue score evaluated using Multidimensional Fatigue Inventory (MFI).	1 week
Primary	Fatigue	Change in fatigue score evaluated using Patient's Global Impression of Change (PGIC) score.	1 week
Primary	Recruitment rate	The number of patients approached, total participants screened for eligibility, and reason for ineligibility or refusal to participate will be documented. We will consider the study successful if we can enroll 40 participants over a 2-year study period, with a recruitment rate of 15%.	2 years
Primary	Completion of intervention	We will consider the intervention to be feasible if at least 75% of enrolled participants complete the full intervention protocol.	2 years
Primary	Completion of follow-up	We will consider the intervention to be feasible if at least 75% of enrolled participants complete all assessments at 1-week follow-up.	2 years
Secondary	Cognition	Change in cognition score evaluated using the Fast Cognitive Evaluation (FaCE).	1 week
Secondary	Cognition	Change in cognition score evaluated using electronic cognitive assessment tool COVID-19 Assessment Battery.	1 week
Secondary	Quality of Life	Change in quality of life score evaluated using McGill Quality of Life Questionnaire-Revised (MQOL-R).	1 week
Secondary	Adverse events	Daily patient-reported adverse effects with specific focus on headache, nausea and vomiting and anxiety, evaluated using the Common Terminology Criteria for Adverse Events (CTCAE).	1 week
Secondary	Patient satisfaction with MFI	Patient satisfaction with MFI as a measure of their fatigue on a 5-point Likert scale.	1 week